Sustained virological response in HCV patients treated with daclatasvir plus sofosbuvir, with or without ribavirin: a multicenter, field-practice experience

被引：0

作者：

Sacco, R. ^{[1
]}

Salomoni, E. ^{[2
]}

Parodi, S. ^{[1
]}

Gianni, E. ^{[3
]}

Gragnani, L. ^{[3
]}

Andreotti, G. ^{[4
]}

Brunetto, M. R. ^{[5
]}

Zignego, A. L. ^{[3
]}

Gattai, R. ^{[5
]}

Vivaldi, I. ^{[6
]}

De Luca, A. ^{[7
]}

Bartolozzi, D. ^{[2
]}

Cinelli, R. ^{[6
]}

Pozzi, M. ^{[2
]}

Coco, B. ^{[5
]}

Tapete, G. ^{[1
]}

Forte, P. ^{[8
]}

Puntili, R. ^{[8
]}

Ricciardi, L. ^{[9
]}

Sani, S. ^{[6
]}

Luchi, S. ^{[9
]}

Valoriani, B. ^{[7
]}

Riccardi, M. P. ^{[4
]}

Nencioni, C. ^{[4
]}

Aquilini, D. ^{[10
]}

Nerli, A. ^{[10
]}

Esperti, F. ^{[11
]}

Mazzotta, F. ^{[11
]}

Bresci, G. ^{[1
]}

Colombatto, P. ^{[5
]}

机构：

[1] Azienda Osped Univ Pisana, UO Gastroenterol & Malattie Ricambio, Pisa, Italy

[2] AOU Careggi, Malattie Infett & Trop, Florence, Italy

[3] AOU Careggi, Ctr MASVE Med Sperimentale & Clin, Florence, Italy

[4] Osped Misericordia, Malattie Infett, Grosseto, Italy

[5] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[6] Spedali Riuniti Livorno, Malattie Infett, Livorno, Italy

[7] Azienda Osped Univ Senese, Malattie Infett, Siena, Italy

[8] AOU Careggi, Gastroenterol 2, Florence, Italy

[9] Osped San Luca, Malattie Infett & Epatol, Lucca, Italy

[10] Nuovo Osped Prato, Malattie Infett, Prato, Italy

[11] Osped S Jacopo, Malattie Infett, Pistoia, Italy

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(17)31958-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-264

引用

页码：S734 / S734

页数：1

共 50 条

[21] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV CO-INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM
Fontaine, H.
Lacombe, K.
Dhiver, C.
Rosenthal, E.
Metivier, S.
Antonini-Michelle, T.
Valantin, M. A.
Cotte, L.
Botero, J.
Harent, S.
Batisse, D.
Pageaux, G. -P.
Aumaitre, H.
Dominguez, S.
De Ledinghen, V.
Leroy, V.
Dabis, F.
Wittkop, L.
Filipovics, A.
Barlet, M. H.
Bennai, Y.
Salmon, D.
JOURNAL OF HEPATOLOGY, 2015, 62 : S275 - S275
[22] Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Hezode, Christophe
de Ledinghen, Victor
Fontaine, Helene
Zoulim, Fabien
Lebray, Pascal
Boyer, Nathalie
Larrey, Dominique G.
Silvain, Christine
Botta-Fridlund, Danielle
Leroy, Vincent
Bourliere, Marc
d'Alteroche, Louis
Fouchard-Hubert, Isabelle
Guyader, Dominique
Rosa, Isabelle
Nguyen-Khac, Eric
Di Martino, Vincent
Carrat, Fabrice
Fedchuk, Larysa
Akremi, Raoudha
Bennai, Yacia
Bronowicki, Jean-Pierre
HEPATOLOGY, 2015, 62 : 314A - 314A
[23] Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin
Nunez, M.
Ocampo, A.
Aguirrebengoa, K.
Cervantes, M.
Pascual, A.
Echeverria, S.
Asensi, V.
Barreiro, P.
Garcia-Samaniego, J.
Soriano, V.
JOURNAL OF VIRAL HEPATITIS, 2008, 15 (05) : 363 - 369
[24] Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a compassionate use program
Welzel, T.
Herzer, K.
Ferenci, P.
Petersen, J.
Gschwantler, M.
Cornberg, M.
Berg, T.
Spengler, U.
Weiland, O.
Van der Valk, M.
Klinker, H.
Rockstroh, J.
Ingiliz, P.
Peck-Radosavljevic, M.
Jimenez-Exposito, M. J.
Zeuzem, S.
JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 4 - 5
[25] Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease
Rockstroh, Juergen K.
Ingiliz, Patrick
Petersen, Joerg
Peck-Radosavljevic, Markus
Welzel, Tania M.
Van der Valk, Marc
Zhao, Yue
Jimenez-Exposito, Maria Jesus
Zeuzem, Stefan
ANTIVIRAL THERAPY, 2017, 22 (03) : 225 - 236
[26] Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α-2a and ribavirin
Yu, Jian-Wu
Wang, Gui-Qiang
Sun, Li-Jie
Li, Xiao-Guang
Li, Shu-Chen
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (06) : 832 - 836
[27] Effect of Ribavirin on the Safety Profile of Daclatasvir Plus Sofosbuvir for Patients With Chronic HCV Infection Presidential Poster
Sulkowski, Mark
Gardiner, David
Hughes, Eric
Huang, Shu-Pang
Grasela, Dennis
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S169 - S169
[28] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV INFECTION AND DECOMPENSATED CIRRHOSIS: INTERIM ANALYSIS OF A FRENCH MULTICENTRE COMPASSIONATE USE PROGRAMME
Leroy, V.
Hezode, C.
Metivier, S.
Tateo, M.
Conti, F.
Nguyen-Khac, E.
Lacoste, D.
Vergniol, J.
Truchi, R.
Guyader, D.
Riachi, G.
Michau, C.
Blaison, D.
Oberti, F.
Fontaine, H.
Di Martino, V.
Bronowicki, J. -P.
Akremi, R.
Bennai, Y.
Filipovics, A.
Pageaux, G. -P.
JOURNAL OF HEPATOLOGY, 2016, 64 : S829 - S829
[29] Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIV-Coinfected Patients
Breilh, Dominique
Djabarouti, Sarah
Trimoulet, Pascale
Le Bail, Brigitte
Dupon, Michel
Ragnaud, Jean-Marie
Fleury, Herve
Saux, Marie-Claude
Thiebaut, Rodolphe
Chene, Genevieve
Neau, Didier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (03) : 428 - 430
[30] High sustained virological response rates for patients with hepatitis C genotype 2 treated with sofosbuvir and ribavirin in the real world: An Australian nursing experience
Leembruggen, N.
Fragomeli, V.
Nazareth, S.
Colman, A.
Spruce, S.
Mason, S.
Weltman, M.
Cheng, W.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 53 - 53

← 1 2 3 4 5 →